• Triple-Negative Breast Cancer — Fifth Annual National General Medical Oncology Summit
    Jun 20 2026

    Featuring perspectives from Dr Adam M Brufsky and Dr Kevin Kalinsky, including the following topics:

    • Introduction (0:00)
    • Current and Future Role of TROP2-Directed Antibody-Drug Conjugates in Therapy for Triple-Negative Breast Cancer (TNBC) — Dr Brufsky (5:08)
    • Established Treatment Paradigm for Localized and Metastatic TNBC — Dr Kalinsky (35:20)

    CME information and select publications

    Show More Show Less
    49 mins
  • HR-Positive Metastatic Breast Cancer — A Discussion and Debate on First- and Second-Line Therapy
    Jun 11 2026

    Dr Sara A Hurvitz from the Fred Hutchinson Cancer Center in Seattle, Washington, and Dr Virginia Kaklamani from the UT Health San Antonio MD Anderson Cancer Center in San Antonio, Texas, discuss patient cases and review relevant data on the management of ER-positive, HER2-negative metastatic breast cancer.

    CME information and select publications

    Show More Show Less
    58 mins
  • Desmoid Tumors — Microlearning Activity 3 with Prof Bernd Kasper
    Jun 2 2026

    Prof Bernd Kasper from the Mannheim Cancer Center in Mannheim, Germany, discusses recent updates on available and novel treatment strategies for desmoid tumors.

    CME information and select publications here.

    Show More Show Less
    23 mins
  • Oral SERDs for Breast Cancer — Year in Review Series on Relevant New Datasets and Advances
    Apr 30 2026

    Dr Aditya Bardia from the University of California Los Angeles and Dr Erica Mayer from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss key clinical trial data surrounding the use of oral SERDs in the management of breast cancer.

    CME information and select publications here.

    Show More Show Less
    57 mins
  • HR-Positive Metastatic Breast Cancer — An Interview with Dr Seth Wander on Optimizing Biomarker Assessment and Related Treatment Decision-Making
    Apr 16 2026

    Dr Seth Wander from Massachusetts General Hospital in Boston discusses the role of biomarker assessment in the management of HR-positive metastatic breast cancer.

    CME information and select publications here.

    Show More Show Less
    1 hr
  • ER-Positive, HER2-Positive Metastatic Breast Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy
    Apr 14 2026

    Dr Virginia F Borges from the University of Colorado Anschutz Medical Campus in Aurora and Dr Ian E Krop from Yale Cancer Center in New Haven, Connecticut, review clinical research data and best practices guiding the selection of first-line and maintenance therapy for patients with ER-positive, HER2-positive metastatic breast cancer.

    CME information and select publications here.

    Show More Show Less
    58 mins
  • Desmoid Tumors — Microlearning Activity 2 with Dr Ravin Ratan
    Apr 7 2026

    Dr Ravin Ratan from The University of Texas MD Anderson Cancer Center in Houston discusses available clinical data with treatment approaches for desmoid tumors, alongside clinical cases illustrating real-world application.

    CME information and select publications here.

    Show More Show Less
    28 mins
  • Diabetology in Breast Cancer — Managing Hyperglycemia in Patients with Breast Cancer Receiving Agents Targeting the PI3K/AKT/PTEN Pathway
    Mar 30 2026

    Ms Jaime Carroll from Mayo Clinic in Rochester, Minnesota, Professor Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy, Dr Marie E McDonnell from Brigham and Women’s Hospital in Boston, Massachusetts, and Dr Hope S Rugo from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss the incidence, prevention and management of hyperglycemia in breast cancer patients receiving PI3K/AKT/PTEN inhibitors.

    CME information and select publications here.

    Show More Show Less
    1 hr and 16 mins